Respi-DART 2026: Invited Speakers
December 9–11, 2026 • Hacienda del Mar, Los Cabos, Mexico
Barry-Wainberg DART Achievement Award Lecture
Ralph Baric, PhD
University of North Carolina, USA
“Decades at the frontlines of emerging viruses and future antiviral innovation”
Jinhong Chang, MD, PhD
Blumberg Institute, USA
“Antiviral therapies: dengue and yellow fever”
Mark Heise, PhD
University of North Carolina Chapel Hill, USA
“Alphavirus helicase inhibitors”
Anna Hirsch, PhD
Helmholtz Institute for Pharmaceutical Research Saarland, Germany
“Optimization of novel respiratory syncytial virus-inhibitors by multi-parametric profiling”
Vince Marconi, MD
Emory University, USA
“Cardiovascular complications of Long-COVID: novel diagnostics and treatments”
Asunción Mejías, MD, PhD
St. Jude Children’s Research Hospital, USA
“Respiratory syncytial virus challenges the paradigm of genetic stability”
Anne Moscona, MD
Columbia University, USA
“Antiviral peptides against parainfluenza viruses”
Plenary Lecture
Ujjwal Neogi, PhD
Karolinska Institutet, Sweden
“Antiviral agents and host factors in combating potential pandemic arboviruses”
Michael Peluso, MD
University of California, San Francisco, USA
“Recommended Long-COVID outcome measures and their implications for clinical trial design, with a focus on post-exertional malaise”
Stanley Perlman, MD, PhD
University of Iowa, USA
“Mouse model system for following long-COVID”
Richard Plemper, PhD
Georgia State University, USA
“Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models”
Angela Rasmussen, PhD
Georgetown University, USA
“On the origins of SARS-CoV-2 and future pandemics”
Boghuma Titanji, MD, PhD
Emory University, USA
“Hantaan virus and Ebola should we take these viruses seriously”
Susan Weiss, PhD
University of Pennsylvania, USA
“Host and virus interactions in the respiratory epithelium”